CTNM — Contineum Therapeutics, Inc. stock price, charts and financials

Latest market price

14.68

-0.37-2.43%

Overview Short InterestFilings

CTNMQT83Contineum Therapeutics, Inc.·NASDAQ

Overview Short InterestFilings

14.68-2.43%

Loading chart...

Signal & projected range

Earnings big beat — drift (PEAD)Historical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

AUPH-2.33%$15.48 MESO+4.96%$16.73 ZBIO-1.46%$31.96 GHRS-2.07%$29.64 TSHA-0.69%$6.51 STOK-1.46%$32.23 ABCL+31.03%$9.08 VRDN-2.29%$23.05

Snapshot

Index	-	P/E	-	EPS (ttm)	-	Insider Own	9.32%	Shs Outstand	37.62M	Perf Week	-2.91%

Market Cap	565.82M	Forward P/E	-	EPS next Y	-1.82	Insider Trans	-2.84%	Shs Float	27.76M	Perf Month	-2.65%

Enterprise Value	557.68M	PEG	-	EPS next Q	-0.43	Inst Own	-	Short Float	8.80%	Perf Quarter	2.80%

Income	-57.77M	P/S	0.00	EPS this Y	-	Inst Trans	-	Short Ratio	7.44	Perf Half Y	3.87%

Sales	0.00	P/B	2.35	EPS next Y	-16.70%	ROA	-22.99%	Short Interest	2.44M	Perf YTD	31.58%

Book/sh	-	P/C	-	EPS next 5Y	-	ROE	-24.73%	52W High	16.50 -11.06%	Perf Year	137.60%

Cash/sh	-	P/FCF	-	EPS past 3/5Y	-	ROIC	-26.96%	52W Low	6.04 142.97%	Perf 3Y	-

Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-	Gross Margin	0.00%	Volatility	7.42% 7.06%	Perf 5Y	-

Dividend TTM	-	EV/Sales	0.00	EPS Y/Y TTM	-6.13%	Oper. Margin	0.00%	ATR (14)	1.11	Perf 10Y	-

Dividend Ex-Date	-	Quick Ratio	37.17	Sales Y/Y TTM	-	Profit Margin	0.00%	RSI (14)	53.29	Recom	2.33

Dividend Gr. 3/5Y	-	Current Ratio	37.17	EPS Q/Q	35.48%	SMA20	2.39%	Beta	0.94	Target Price	16.00

Payout	0.00%	Debt/Eq	0.03	Sales Q/Q	-	SMA50	8.73%	Rel Volume	1.70	Prev Close	15.04

Employees	51	LT Debt/Eq	0.02	Earnings	Oct 29	SMA200	15.75%	Avg Volume	311.56K	Price	14.68

IPO Date	Apr 04, 2024	Option/Short	Yes / Yes	EPS/Sales Surpr.	10.87% -	Net Debt/EBITDA	0.12	Volume	528,931	Change	-2.43%

Analyst Ratings

Date	Action	Analyst	Rating	Target
May-14-26	Reiterated	Morgan Stanley	Equal Weight	$14 → $16
Jan-08-26	Downgrade	Morgan Stanley	Overweight → Equal Weight	$14
Nov-24-25	Reiterated	Robert W. Baird		$16 → $14
Nov-21-25	Reiterated	RBC Capital	Outperform	$30 → $22
Sep-25-25	Initiated	Leerink	Outperform	$20
Mar-07-25	Reiterated	Robert W. Baird		$32 → $16
Oct-21-24	Reiterated	Robert W. Baird		$32
Apr-30-24	Initiated	RBC Capital	Outperform	$30
Apr-30-24	Reiterated	Stifel Nicolaus		$29

Latest News

Jul-31-26

Jul-31-2602:43PM

RBC Capital Maintains Outperform on Contineum Therapeutics, Raises Price Target to $23Benzinga

Jul-30-26

Jul-30-2604:05PM

Contineum Therapeutics Reports Second-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestonesbusinesswire.com

Jul-09-26

Jul-09-2601:01PM

Are You Looking for a Top Momentum Pick? Why Contineum Therapeutics, Inc. (CTNM) is a Great Choicezacks.com

Jun-30-26

Jun-30-2605:01PM

Contineum Therapeutics Publishes Discovery of Potential Best-in-Class LPAR1 Antagonist PIPE-791 in Journal of Medicinal Chemistrygurufocus.com

04:08PM

Contineum Therapeutics Publishes 'Discovery of PIPE-791, a Potent and Brain-Penetrant Lysophosphatidic Acid Receptor 1 (LPAR1) Antagonist with Slow Tight Binding Characteristics for the Treatment of Neuroinflammatory Disorders' In Journal of Medicinal ChemistryBenzinga

Company

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company’s lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is based in San Diego, California.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021
Total Revenue	0	0	50	—	—
Cost of Goods Sold Incl. D&A	0	0	0	—	—
Gross Profit	0	0	50	—	—
Selling, General and Administrative Excl. Other	17	12	6	—	—
Research and Development	52	38	28	—	—
Other Operating Expense	-1	1	32	—	—
Operating Income	-68	-51	-16	—	—
Interest Expense	0	0	0	—	—
Unusual Expense	—	—	—	—	—
Non-Operating Income (Expense)	8	9	39	—	—
Net Income Before Taxes	-60	-42	23	—	—
Income Taxes	0	0	0	—	—
Consolidated Net Income	-60	-42	23	—	—
Net Income From Continuing Operations	-60	-42	23	—	—
Net Income	-60	-42	23	—	—
EPS (Recurring)	-2.17	-1.63	0.13	—	—
EPS (Basic, Before Extraordinaries)	-2.17	-1.63	0.13	—	—
EPS (Diluted)	-2.17	-1.63	0.13	—	—
EBITDA	-68	-42	24	—	—
Other After Tax Adjustments	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—
Price To Earnings Ratio	—	—	—	—	—
Price To Sales Ratio	—	—	—	—	—
Gross Margin	—	—	100.00	—	—
Operating Margin	—	—	-32.00	—	—
Net Margin	—	—	46.00	—	—
Shares Outstanding	28	26	25	—	—
Market Capitalization	320	381	—	—	—
Operating Lease Expense	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Stengone Carmine N.	CEO and President	Aug 03 '26	Sale	16.01	2,500	40,029	17,217	Aug 03
Stengone Carmine N.	CEO and President	Aug 03 '26	Option Exercise	1.01	2,500	2,525	19,717	Aug 03
Lorrain Daniel S.	Chief Scientific Officer	Jul 09 '26	Option Exercise	1.01	25	25	135,227	Jul 10
Lorrain Daniel S.	Chief Scientific Officer	Jul 09 '26	Sale	16.00	25	400	135,202	Jul 10
Lorrain Daniel S.	Chief Scientific Officer	Jul 08 '26	Option Exercise	1.01	1,015	1,025	136,217	Jul 10
Stengone Carmine N.	CEO and President	Jul 08 '26	Sale	16.00	2,500	40,000	17,217	Jul 08
Stengone Carmine N.	CEO and President	Jul 08 '26	Option Exercise	1.01	2,500	2,525	19,717	Jul 08
Lorrain Daniel S.	Chief Scientific Officer	Jul 01 '26	Option Exercise	1.01	4,183	4,225	143,555	Jul 02
Lorrain Daniel S.	Chief Scientific Officer	Jul 01 '26	Sale	15.84	8,353	132,290	135,202	Jul 02
Lorrain Daniel S.	Chief Scientific Officer	Jun 30 '26	Option Exercise	1.01	28,826	29,114	168,198	Jul 02
Lorrain Daniel S.	Chief Scientific Officer	Jun 30 '26	Sale	16.04	28,826	462,288	139,372	Jul 02
Watkins Tim	CMO & Head of Development	Jun 30 '26	Option Exercise	4.50	10,833	48,749	19,794	Jul 01
Watkins Tim	CMO & Head of Development	Jun 30 '26	Sale	16.02	10,833	173,590	8,961	Jul 01
Stengone Carmine N.	CEO and President	Jun 30 '26	Option Exercise	1.07	10,000	10,725	27,217	Jul 01
Stengone Carmine N.	CEO and President	Jun 30 '26	Sale	16.01	10,000	160,080	17,217	Jul 01

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.